Abstract:BACKGROUND: Despite IFNalpha has been used extensively in the treatment of multiple myeloma (MM), there are also several reports suggesting that IFNalpha may aggravate isease in some MM patients. That means the effect of IFNalpha on the growth of myeloma cells in vivo may be different. In this study, we selected two human myeloma cell lines that vary remarkably in response to IFNalpha and focused on elucidating the mechanism of differential IFNalpha responsiveness. RESULTS: Sko-007 is a myeloma cell line whose growth is arrested by IFNalpha; however, IFNalpha promoted the proliferation of the other myeloma cell line U266. We observed that the growth-stimulation effect of IFNalpha on U266 cells did not result from up-regulation of the IL-6 receptors on cell surface; while IFNalpha treatment on Sko-007 cells significantly reduced gp130 expression. Moreover, the transcription factors STAT3 and STAT1, which are involved in the JAK/STAT signal transduction pathway, can be activated in both IFNalpha-stimulated and -inhibited myeloma cell lines; while the activation of the protein kinase ERK, which is involved in the Ras/MAPK signal transduction pathway, can be down-regulated in IFNalpha-arrested Sko-007 cells and up-regulated in IFNalpha-stimulated U266 cells. In addition, both IFNalpha-induced growth-stimulation effect and the up-regulated activation of ERK in U266 cells were efficiently inhibited by PD98059, the specific inhibitor of MAPK/ERK kinase (MEK). CONCLUSION: Myeloma cells responsiveness to IFNalpha is heterogeneous and the activation state of ERK in the Ras/MAPK signalling pathway mainly contributed to this difference.

[Study of IL-6 Signal Transduction Pathway in a Human Multiple Myeloma Cell Line--sko-007].

Association and Contribution of Erk to Il-6-Induced Activation of Signal Transducer and Activator of Transcription in A Human Myeloma Cell Line

The biological function of IL-6 on a human multiple myeloma cell-KM-3 is mediated by Ras/NF-IL-6 signal transduction pathway

Function of tyrosine kinase JAK1 in IL-6-induced activation of JAK/STAT signal transduction pathway

Interleukin-32 Induce Production of Il-6 in Multiple Myeloma Bone Marrow Stromal Cells

Inhibition of IL-6-induced STAT3 Activation in Myeloma Cells by Protein Kinase A

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Antagonistic effect between two IL-6 signal transduction pathways in a human myeloma cell line-U266

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha.

Camp Inhibits the Proliferation and IL-6 Signal Transduction of Multiple Myeloma Cell

[Study on the Biological Activity and Molecular Mechanism of IFNalpha on Human Myeloma Cell Line Sko-007].

IL-6 Inhibits Apoptosis of Human Myeloma Cell Line XG-7 Through Activation of JAK/STAT Pathway and Up-Regulation of Mcl-1.

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNα

Interleukin-32 Alpha Promotes The Proliferation Of Multiple Myeloma Cells By Inducing Production Of Il-6 In Bone Marrow Stromal Cells

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

[Activation of PKA Pathway Inhibits Reactivity of Human Myeloma Cell Line-U266 to IL-6].

Involvement of STAT3/APRF in IL-6 signal transduction pathway

Relationship between IL-6 signal transduction pathways and its growth effect on a human myeloma cell line-U266

A soluble interleukin-6 receptor mutant inhibits interleukin-6-induced signal transduction in myeloma cells

The expression and role of IL-6, IL-6R and acute phase reaction factor in peripheral blood mononuclear cells of multiple myeloma

Expressions of IL-1β,IL-6,SCF,TPO on Bone Marrow Stromal Cells in Patients with Multiple Myelo-Ma